MedPath

Study on the Safety, Tolerability and Efficacy of the Aqua Medical focal vapor ablation system, for the eradication of Barrett's Esophagus - part 2

Not Applicable
Recruiting
Conditions
<p>Barrett esophagus, Barrett neoplasia</p>
10017991
Registration Number
NL-OMON20279
Lead Sponsor
Aqua Medical, Inc.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
19
Inclusion Criteria

Flat Barrett's esophagus (BE) with an indication for ablation therapy ( either flat confirmed LGD, flat HGD, or residual flat BE after endoscopic resection of early, non-flat BE neoplasia)

Exclusion Criteria

Presence of visible lesions, history of advanced BE neoplasia (either sm2+, LVI+ or G3+).

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>BE surface regression after 8-12 weeks FU, incidence of adverse events</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Feasibility to ablate the entire area as intended, duration of ablation, device malfunction, pain scores</p><br>
© Copyright 2025. All Rights Reserved by MedPath